ScreenerHero

ALM Almirall, S.A.

BME · ES · Healthcare · Drug Manufacturers - Specialty & Generic · almirall.com
10.10EUR-1.56%Mkt Cap: 2.39B $P/E: 30.61

Almirall, S.A. operates as a skin health-focused biopharmaceutical company in Spain, Europe, the Middle East, the United States, Asia, and Africa. The company offers its products for skin diseases comprising Psoriasis, a…

Industry Peers

Drug Manufacturers - Specialty & Generic
Screen all
MRK
Merck KGaA
$64.30BUSDP/E 25.0
TAK
Takeda Pharmaceutical Company Limited
$56.90BUSD
TEVA
Teva Pharmaceutical Industries Limited
$46.26BUSDP/E 66.1
HLN
Haleon plc
$38.79BUSDP/E 18.0
ZTS
Zoetis Inc.
$29.51BUSDP/E 11.7
ZOE
Zoetis Inc.
$28.27BUSDP/E 12.1
UTHR
United Therapeutics Corporation
$23.01BUSDP/E 19.2
VTRS
Viatris Inc.
$20.24BUSD
SOBI
Swedish Orphan Biovitrum AB (publ)
$14.14BUSDP/E 110.6
NBIX
Neurocrine Biosciences, Inc.
$14.66BUSDP/E 21.1
IPN
Ipsen S.A.
$12.60BUSDP/E 22.8
ELAN
Elanco Animal Health Incorporated
$11.25BUSD
RDY
Dr. Reddy's Laboratories Limited
$10.26BUSDP/E 28.0
KRK
Krka, d. d.
$8.59BUSDP/E 19.2
ALKS
Alkermes plc
$7.17BUSDP/E 112.5
AMRX
Amneal Pharmaceuticals, Inc.
$7.09BUSDP/E 41.5
HIMS
Hims & Hers Health, Inc.
$6.92BUSD
LNTH
Lantheus Holdings, Inc.
$6.54BUSDP/E 24.3
KNSA
Kiniksa Pharmaceuticals International, plc
$5.87BUSDP/E 77.1
APTX
Apotex Health Corp.
$5.17BUSD

Key Statistics

Company
Market Cap2.39B USD
Enterprise Value2.43B USD
Revenue (TTM)1.26B USD
Gross Profit947.41M USD
Net Income (TTM)50.17M USD
Revenue/Share5.41 EUR
Last Price10.10 EUR
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees2.1K
CountryES
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
ISINES0157097017
Valuation
P/E (Trailing)30.61
P/E (Forward)18.97
PEG1.00
EV/EBITDA10.13
EV/Revenue1.93
P/S1.92
P/B1.45
EPS (TTM)0.33
EPS (Forward)0.54
52W Range
10.022% of range13.98
52W High13.98 EUR
52W Low10.02 EUR
Profitability
Gross Margin78.66%
Oper. Margin13.34%
EBITDA Margin19.05%
Profit Margin4.17%
ROE3.10%
ROA1.97%
Growth
Revenue Growth13.00%
Earnings Growth435.10%
Cash Flow & Leverage
Operating CF189.63M USD
CapEx (TTM)149.25M USD
FCF Margin6.50%
FCF Yield3.42%
Net Debt8.98M USD
Net Debt/EBITDA0.04
Balance Sheet
Debt/Equity0.23
Current Ratio2.31
Quick Ratio1.70
Book Value/Sh7.03 EUR
Cash/Share1.63 EUR
Dividends
Fwd Div Rate0.19 EUR
Trail. Div Rate0.19 EUR
Div. Yield1.83%
5Y Avg Yield1.83%
Payout Ratio66.79%
Ex-Div DateMay 14, 2026
Pay Date—
Analyst Consensus
Rating—
Target (Mean)14.32 EUR
Upside (mean)+41.8%
Target Range11.50 EUR – 17.50 EUR
11.50+41.8% to mean17.50
# Analysts12
Ownership
Shares Out.217.61M
Float78.27M
Insiders64.07%
Institutions16.81%
Technical
SMA 5010.58 (-4.5%)
SMA 20011.74 (-13.9%)
Beta0.17
S&P 52W Chg14.58%
Avg Vol (30d)91.16K
Avg Vol (10d)111.76K
Technical Indicators
RSI (14)40.4
MACD-0.0628
MACD Signal-0.0411
MACD Hist.-0.0217
BB Upper10.76 EUR
BB Middle10.39 EUR
BB Lower10.02 EUR
BB Width7.18%
ATR (14)0.2349 EUR
Vol Ratio (20d)0.61x